Company intelligence / Profile preview
AllianThera Biopharma
Suzhou, Jiangsu Sheng, Chinaprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
No detailed public clinical results are available yet. The company is progressing through preclinical studies into Phase I trials focusing on efficacy and safety of their small molecule candidates targeting immune-related pathways such as AhR.
- Therapeutic areas
- OncologyImmunologyOther
- Modalities
- Small molecule drugsPotential use of AI-driven drug discovery platforms
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Major collaboration with Insilico Medicine focused on AI-powered target discovery and drug design since March 2021
Beyond the preview
Go deeper on AllianThera Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AllianThera Biopharma.